Nejat Jalisi, MD
Family Medicine · El Cajon, CANPI 1063651552
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 451 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,976, 3.7 times the $797 reported in 2019. Among family medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 451 payments — averaging $23.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Bayer$940
- AstraZeneca$935
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$780
- Novo Nordisk$770
- Lilly USA, LLC$728
- plus $5K from 35 others
What the payments were for
- Travel & lodging$2282%
- Food & beverage$10,37298%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$308
- Repatha$245
- Kerendia$233
- Omnipod$169
- CardioMEMS HF System$148
- ZEPBOUND$124
- Saxenda$122
- Auvelity$122
How this compares
$10,620 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 180 | $172,353 |
| FarxigaDapagliflozin Propanediol | 237 | $149,130 |
| JardianceEmpagliflozin | 149 | $110,394 |
| RybelsusSemaglutide | 112 | $105,742 |
| KerendiaFinerenone | 154 | $100,471 |
| MounjaroTirzepatide | 89 | $88,239 |
| JanuviaSitagliptin Phosphate | 94 | $66,444 |
| LinzessLinaclotide | 83 | $44,694 |
| TrulicityDulaglutide | 41 | $41,891 |
| TrulancePlecanatide | 69 | $35,662 |
| EliquisApixaban | 31 | $24,749 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $21,339 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $17,085 |
| TradjentaLinagliptin | 34 | $16,872 |
| EntrestoSacubitril/Valsartan | 21 | $14,557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $770 | $278,094292 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $935 | $178,708288 claims |
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi | $728 | $137,030144 claims |
| Boehringer IngelheimJardiance, Tradjenta | $151 | $127,266183 claims |
| BayerKerendia | $940 | $100,471154 claims |
| MerckJanuvia, Janumet | $160 | $80,995121 claims |
| AbbVieLinzess | $1,174 | $44,69483 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $780 | $35,66269 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $400 | $31,47652 claims |
| PfizerEliquis | $594 | $24,74931 claims |
| NovartisEntresto | $134 | $14,55721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in El Cajon
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.